Ischemic Stroke Overview

Principles

Definition

Ischemic stroke is a major focus within biomedical research and clinical science investigating the etiology, pathophysiology, diagnosis, treatment, and long-term consequences of cerebral ischemia leading to brain infarction. This multidisciplinary field encompasses studies ranging from cellular and molecular mechanisms and advanced neuroimaging to clinical trials, epidemiology, and rehabilitation science, driven by its status as a leading cause of global disability and mortality.

Ontological type

Pathophysiological Mechanisms

Acute Therapeutic Interventions

Etiology and Risk Factors

Key developments

Key Figures

Foundational Reperfusion Framework era

J. van Gijn [1], affiliated with Erasmus University Rotterdam [3] and University College London [4] during the Foundational Reperfusion Framework era, helped define time-sensitive approaches to ischemic stroke. His key contribution in this era, the paper Interobserver agreement for the assessment of handicap in stroke patients [7], established standardized functional outcome measures that enabled reliable cross-study comparisons and informed trial design. Peter J. Koudstaal [2], associated with Rotterdam University of Applied Sciences [5] and Utrecht University [6] during this era, contributed to the development of outcome assessment frameworks in stroke. As a co-author on the same 1988 paper Interobserver agreement for the assessment of handicap in stroke patients [7], Koudstaal's work reinforced the need for reliable inter-rater scoring to support prognosis, registries, and the planning of reperfusion strategies in this foundational period.

Imaging-Guided Thrombolysis Era era

Werner Hacke[1] is a prominent neurologist whose work in the Imaging-Guided Thrombolysis Era spanned institutions such as Harvard University[3] and Johns Hopkins University[4]. His key contributions include the Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [7], Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke—The European Cooperative Acute Stroke Study (ECASS) [8], and Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study [9], which collectively established safety, time-windowed efficacy, and the role of imaging-based patient selection. Markku Kaste[2] is a leading figure in this era with affiliations to Karolinska Institutet[5] and Heidelberg University[6]. His contributions include the ECASS II [7], the SITS-MOST [9], and the MATCH trial [10], illustrating how this era refined thrombolysis safety, imaging-guided selection, and post-stroke antithrombotic strategies.

Endovascular Reperfusion Implementation era

Ralph L. Sacco [1] is a leading figure in vascular neurology associated with Harvard University [3] and the Massachusetts Institute of Technology [4] during the Endovascular Reperfusion Implementation era. His work on Heart Disease and Stroke Statistics—2010 Update [6], the INTERSTROKE study [7], and the World Stroke Organization Global Stroke Fact Sheet 2022 [8] synthesized global burden and risk patterns, providing essential epidemiologic context that underpins guideline harmonization, imaging-based triage, and quality-improvement efforts in endovascular reperfusion programs. Karen L. Furie [2] is a leading scholar affiliated with Harvard University [3] and the University of California, San Francisco [5] during this era. Her contributions through the Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack (2010 [10]) and Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2014 [9]), along with the Heart Disease and Stroke Statistics—2010 Update [6], established standardized prevention frameworks that underpin risk-factor management and guideline harmonization essential to scalable endovascular reperfusion pathways.